Your session is about to expire
What is Levonest
LevonorgestrelThe Generic name of this drug
Treatment SummaryLevonorgestrel (LNG) is a synthetic hormone used in contraception and hormone therapy. It is most commonly known as Plan B and is used as a single agent in emergency contraception, as an IUD, or as an implant that slowly releases the hormone over a long period of time. Levonorgestrel is the most widely used emergency contraceptive in the world and was approved by the FDA in 1982. It is highly effective and has few estrogenic side effects when compared to older emergency contraceptive regimens.
Triphasil-21is the brand name
Levonest Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Triphasil-21
Levonorgestrel
1984
243
Approved as Treatment by the FDA
Levonorgestrel, also known as Triphasil-21, is approved by the FDA for 6 uses including moderate Menopausal Vasomotor Symptoms and Emergency Contraception .moderate Menopausal Vasomotor Symptoms
Used to treat moderate Menopausal Vasomotor Symptoms in combination with Estradiol
Emergency Contraception
Has had at least 1 child
Postmenopausal Osteoporosis
Used to treat Postmenopausal Osteoporosis in combination with Estradiol
Menopause
Used to treat severe Vasomotor Symptoms Associated With Menopause in combination with Estradiol
Hot flashes
Used to treat Menopause in combination with Estradiol
Effectiveness
How Levonest Affects PatientsLevonorgestrel is a contraceptive medication that works by preventing ovulation, fertilization, and implantation to prevent pregnancy. If taken within 72 hours after intercourse, it is 89% effective. When combined with other hormones, it can help reduce the risk of endometrial cancer. Levonorgestrel devices, such as implants and intrauterine devices, are more than 99% effective in preventing pregnancy.
How Levonest works in the bodyLevonorgestrel is a hormone used in oral contraceptives to prevent pregnancy. It works by preventing ovulation and thickening cervical mucus, making it harder for sperm to enter the uterus. Levonorgestrel may also have an effect on endometrial receptivity, meaning it could potentially prevent a fertilized egg from implanting in the uterus. When combined with estrogen for menopausal symptom relief, levonorgestrel may reduce the risk of endometrial cancer by inhibiting endometrial growth.
When to interrupt dosage
The measure of Levonest is contingent upon the diagnosed condition, including Endometrial Hyperplasia, Emergency Contraception and Hypermenorrhea. The amount of dosage pivots on the delivery approach referred to in the table below.Condition
Dosage
Administration
Emergency Contraception
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Endometrial Hyperplasia
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Menopause
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Hypermenorrhea
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
moderate Menopausal Vasomotor Symptoms
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Postmenopausal Osteoporosis
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Endometriosis
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Has had at least 1 child
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Hot flashes
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Warnings
Levonest has forty-three contraindications and should not be taken when one is enduring the conditions specified in the following table.Levonest ContraindicationsCondition
Risk Level
Notes
Septic Abortion
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
infected abortions
Do Not Combine
HCG elevated
Do Not Combine
Pelvic Infection
Do Not Combine
Vaginitis
Do Not Combine
Acute Coryza
Do Not Combine
presence or history of breast cancer
Do Not Combine
Uterine Cervicitis
Do Not Combine
Communicable Diseases
Do Not Combine
gonococcal cervical infection
Do Not Combine
Breast Cancer
Do Not Combine
Intrauterine Devices
Do Not Combine
Neoplasms, Hepatic
Do Not Combine
congenital or aquired uterine abnormality
Do Not Combine
Chlamydia Infections
Do Not Combine
Hypersensitivity
Do Not Combine
Emergency Contraception
Do Not Combine
Bacterial Endocarditis
Do Not Combine
lower genital tract infection
Do Not Combine
suspected pregnancy
Do Not Combine
Uterine Cervicitis
Do Not Combine
uterine neoplasia
Do Not Combine
Pelvic Inflammatory Disease
Do Not Combine
history of progestogen-sensitive breast cancer
Do Not Combine
Cervical Neoplasia
Do Not Combine
Fibroid Tumor
Do Not Combine
Postpartum Endometritis
Do Not Combine
chlamydial cervical infection
Do Not Combine
PAP Test Abnormalities
Do Not Combine
acute liver disease
Do Not Combine
Uterine anomaly distorting uterine cavity
Do Not Combine
Breast Cancer
Do Not Combine
Cervical Dysplasia
Do Not Combine
Thromboembolism
Do Not Combine
Bacterial Vaginosis
Do Not Combine
history of pelvic inflammatory disease
Do Not Combine
Breast
Do Not Combine
Vaginal Bleeding
Do Not Combine
Bacterial Vaginosis
Do Not Combine
Pelvic Inflammatory Disease
Do Not Combine
gonococcal cervical infection
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Levonorgestrel may interact with Pulse Frequency
Common Levonest Drug Interactions
Drug Name
Risk Level
Description
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Levonorgestrel.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Levonorgestrel.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Levonorgestrel.
Copanlisib
Major
The metabolism of Copanlisib can be decreased when combined with Levonorgestrel.
Crizotinib
Major
The metabolism of Crizotinib can be decreased when combined with Levonorgestrel.
Levonest Toxicity & Overdose RiskThe lowest dose that results in toxicity for rats is greater than 5000mg/kg. Overdosing on levonorgestrel can cause nausea and bleeding. Treat the symptoms, and contact the local poison control center if needed. There is no specific antidote for a levonorgestrel overdose.
Levonest Novel Uses: Which Conditions Have a Clinical Trial Featuring Levonest?
Currently, 99 active experiments are being conducted to assess the potential of Levonest in managing Postmenopausal Osteoporosis, Women who have had at least one Child, and Endometrial Hyperplasia.Condition
Clinical Trials
Trial Phases
Endometriosis
32 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 2, Phase 4, Phase 1
Menopause
0 Actively Recruiting
Hot flashes
22 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1
Has had at least 1 child
0 Actively Recruiting
Emergency Contraception
1 Actively Recruiting
Phase 4
Endometrial Hyperplasia
9 Actively Recruiting
Phase 2, Not Applicable
Hypermenorrhea
0 Actively Recruiting
Postmenopausal Osteoporosis
3 Actively Recruiting
Not Applicable, Phase 4
moderate Menopausal Vasomotor Symptoms
0 Actively Recruiting
Patient Q&A Section about levonest
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Zumandimine a Yaz?
"This medication is used to prevent pregnancy. It may also be used to treat premenstrual dysphoric disorder (PMDD) or acne in women who are using birth control pills for contraception.
This medication is used as a birth control pill to prevent pregnancy and also to treat premenstrual dysphoric disorder (PMDD) or acne in women."
Answered by AI
What is Levonest used for?
"This medication, which contains a combination of two hormones (a progestin and an estrogen), is used to prevent pregnancy. In addition to preventing pregnancy, birth control pills may also make your periods more regular, decrease the amount of blood loss and pain associated with periods, decrease your risk of developing ovarian cysts, and treat acne."
Answered by AI
Is Yaz same as Jasmiel?
"There are many brand names for this medication."
Answered by AI
When should I start taking Jasmiel?
"Tell the patient to start taking Jasmiel on either the first day of her period (Day 1 Start) or the first Sunday after her period begins (Sunday Start)."
Answered by AI